Abstract

The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada-the largest published cluster in North America. To describe the epidemiology of the Kappa variant in relation to other circulating SARS-CoV-2 variants of concern (VOC) in the region to determine if the epidemiology of the Kappa variant supports a VOI or VOC status. Clinical specimens testing positive for SARS-CoV-2 collected between March 10 and May 2, 2021, were screened for the detection of known circulating VOCs; approximately 50% of specimens were subsequently selected for whole genome sequencing (WGS). Epidemiological analysis was performed comparing the characteristics of Kappa cases to the main circulating variants in the region (Alpha and Gamma) and to non-VOC/VOI cases. A total of 2,079 coronavirus disease 2019 (COVID-19) cases were reported in the region during the study period, of which 54% were selected for WGS. The 1,131 sequenced cases were categorized into Kappa, Alpha, Gamma and non-VOC/VOI. While Alpha and Gamma cases were found to have a significantly higher attack rate among household contacts compared to non-VOI/VOC cases, Kappa was not. Epidemiological analysis supports the designation of Kappa as a VOI and not a VOC. The Alpha and Gamma variants were found to be more transmissible, explaining their subsequent dominance in the region and the rapid disappearance of the Kappa variant. Variant surveillance strategies should focus on both detection of established VOCs and detection of potential new VOCs.

Highlights

  • The B.1.617 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant was designated as the fourth variant of concern (VOC) by the World Health Organization (WHO) in May 2021 due to concerns of higher transmissibility and potential decreased effectiveness of treatment and vaccines (1)

  • *Correspondence: shaherazad.ghafari@islandhealth. ca Results: A total of 2,079 coronavirus disease 2019 (COVID-19) cases were reported in the region during the study period, of which 54% were selected for whole genome sequencing (WGS)

  • Epidemiological analysis supports the designation of Kappa as a variant of interest (VOI) and not a VOC

Read more

Summary

Introduction

The B.1.617 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant was designated as the fourth variant of concern (VOC) by the World Health Organization (WHO) in May 2021 due to concerns of higher transmissibility and potential decreased effectiveness of treatment and vaccines (1). The epidemiology of Kappa within a region of British Columbia, Canada, from March 10 to May 2, 2021 is reported in relation to other circulating variants. The objective of this analysis is to determine if the epidemiology of Kappa supports this downgrading to a VOI status, or if Kappa is epidemiologically similar to concurrently circulating VOCs. CCDR January 2022 Vol 48 No 1. The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada—the largest published cluster in North America

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.